TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01823562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Follow a low ellagitannin diet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02626338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study: NCT00032487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
Study: NCT03951987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 ml CG5503
Description: 4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 ml CG5503
Description: 4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 g charcoal powder
Description: Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
Study: NCT00919659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: parenteral nutrition
Description: 25kcal/kg bw with parenteral nutrition
Study: NCT02803034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number- SR15-60-Z15-030).
Study: NCT00087295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depsipeptide
Description: Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
Study: NCT02545803

Intervention type: DEVICE
Group type: OTHER
Intervention: Near-Infrared Spectroscopy (NIRS)
Description: Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
Study: NCT00849030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastozole (Arimidex)
Description: 1mg, orally, once daily
Study: NCT00896233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRE
Description: Part 1: Participants will have a screening visit, followed \~1 month later by two imaging visits over \~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed \~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans.
Study: NCT04174742

Intervention type: DRUG
Intervention: pegfilgrastim
Description: It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.

Intervention type: DRUG
Intervention: pegfilgrastim
Description: It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
Study: NCT04885439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NextSteps
Description: Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.
Study: NCT01284192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3026
Description: Tablet
Study: NCT01671904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
Study: NCT01016899

Intervention type: RADIATION
Intervention: electronic brachytherapy
Description: Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
Study: NCT03204695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous LAA Closure
Description: LAA Closure with the WaveCrest LAA Occlusion System (study device)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation or Clopidogrel
Description: Subjects either continue on anticoagulation or receive clopidogrel
Study: NCT01817634

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish powder corn-soy blend'+ Fish oil capsule.
Description: Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish powder corn-soy blend + corn oil capsule.
Description: Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn-soy blend + fish oil capsule.
Description: control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy blend + corn oil capsule.
Description: control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
Study: NCT01628302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lowering salt in diet
Description: Low salt diet (50mmol)for three weeks.
Study: NCT02790216

Intervention type: PROCEDURE
Intervention: Brachytherapy
Description: Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
Study: NCT03990714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right hemicolectomy
Description: It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right hemicolectomy
Description: It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
Study: NCT01671904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV infusion of obinutuzumab (100 milligrams \[mg\]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV infusion of rituximab (375 mg/m\^2) on Day 1 of Cycle 1 and 500 mg/m\^2 administered on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV infusion of rituximab (375 mg/m\^2) on Day 1 of Cycle 1 and 500 mg/m\^2 administered on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.
Study: NCT01587963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: 66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ringers Lactate or Normal Saline
Description: Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
Study: NCT01613612

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: core decompression
Description: minimal surgical invention to drill a core to the femoral head to release pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enriched BMCs implantation combined with core decompression
Description: Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
Study: NCT02211339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer facilitator training
Description: Peer facilitation of a project-based activity without staff present

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Staff-led social activity
Study: NCT00430040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Controlled Release (CR)
Description: lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
Study: NCT00825071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8 mg, Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg, intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2 ml, intravenously
Study: NCT02139189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-ECM Implant
Description: P-ECM Implant into damaged ischemic and/or infarcted myocardium
Study: NCT01358110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care consultation
Description: Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Standard care as usual which may or may not include palliative care consultation
Study: NCT04807491

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kabat Technique's
Description: As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises
Study: NCT00849030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastozole (Arimidex)
Description: 1mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (Nolvadex)
Description: 20mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (Nolvadex)
Description: 20mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastozole (Arimidex) placebo
Description: 1mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (Nolvadex) placebo
Description: 20mg, orally, once daily
Study: NCT00848146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopically assisted Laparoscopic Cholecystectomy Surgery
Description: Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
Study: NCT02299453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT
Description: Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
Study: NCT02184845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant NobelActive 3.0
Study: NCT02022254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Semaglutide placebo will be administered s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
Study: NCT01534663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine and Fish Oil Supplementation
Description: This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
Study: NCT01607918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)
Description: D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D1-D14: (lansoprazole + clarithromycin + amoxicillin)
Description: D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
Study: NCT02468518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E capsule
Description: Capsules will be distributed to each participant free of cost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E capsule
Description: Capsules will be distributed to each participant free of cost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E capsule
Description: Capsules will be distributed to each participant free of cost
Study: NCT03166345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of Thin Endometrium
Description: This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of Thin Endometrium
Description: This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
Study: NCT05956561

Intervention type: OTHER
Intervention: dental implants were placed for all cases while assessing vitamin D levels
Description: vitamin D assessment with measuring implant stability and clinical finding of early failure
Study: NCT01874561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custirsen
Description: Custirsen will be administered iv using an infusion pump over a 2-hour period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
Study: NCT00272779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: 300mg Oral capsules for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: 100mg Oral Capsules for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: 100mg Oral Capsules for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovi-Emtricitabine (TDF/FTC) tablet
Description: One tablet with 300 mg - 200 mg once a day for 96 weeks.
Study: NCT00715416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitinol stent
Description: Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol stent
Description: Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.